Omolola Fagboyegun, APRN
Psychiatric/Mental Health · Dallas, TXNPI 1982322814
Payments from drug & device makers
Across 162 payments — averaging $38.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$992
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$802
- Janssen Scientific Affairs, LLC$412
- Otsuka America Pharmaceutical, Inc.$385
- plus $805 from 5 others
What the payments were for
- Food & beverage$5,88095%
- Education$3215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 29 | $1,406 |
| Teva Pharmaceuticals USA, Inc. | 45 | $1,399 |
| Johnson & Johnson | 23 | $992 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $802 |
| Janssen Scientific Affairs, LLC | 3 | $412 |
| Otsuka America Pharmaceutical, Inc. | 14 | $385 |
| Indivior Inc. | 16 | $340 |
| Luye Pharma (USA) Ltd. | 5 | $207 |
| Alkermes, Inc. | 7 | $167 |
| AbbVie | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$648
- CAPLYTA$605
- INGREZZA$524
- UZEDY$363
- ERZOFRI EXTENDED-RELEASE$128
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
How this compares
$6,201 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 56 | $458,706 |
| Invega SustennaPaliperidone Palmitate | 86 | $251,490 |
| PerserisRisperidone | 21 | $56,073 |
| Abilify MaintenaAripiprazole | 14 | $40,440 |
| Lurasidone Hcl | 28 | $16,817 |
| Aripiprazole | 131 | $5,502 |
| Paliperidone ErPaliperidone | 11 | $5,470 |
| Olanzapine | 232 | $3,838 |
| Doxepin Hcl | 141 | $3,757 |
| Quetiapine Fumarate | 270 | $2,945 |
| Haloperidol | 103 | $2,918 |
| Fluphenazine Hcl | 28 | $2,818 |
| Haloperidol Decanoate | 64 | $2,734 |
| Divalproex Sodium | 177 | $2,734 |
| Benztropine Mesylate | 286 | $2,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,406 | $458,70656 claims |
| Johnson & JohnsonInvega Sustenna | $992 | $251,49086 claims |
| Indivior Inc.Perseris | $340 | $56,07321 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $385 | $40,44014 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $1,399 | $69214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Dallas
- Kimberly ThompsonDallas$25K
- Melissa RiveraDallas$19K
- Jillian AdamsDallas$13K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.